Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TECX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| TX000045 | Hypertension, Pulmonary | Phase 2 · NCT07473700 | Recruiting |
| TX000045- Dose A | Pulmonary Hypertension | Phase 2 · NCT06616974 | Active not recruiting |
| TX000045- Dose B | Pulmonary Hypertension | Phase 2 · NCT06616974 | Active not recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TECX holds $227.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $19.9M/quarter from operations, an estimated runway of 34.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TECX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Timothy A. Springer | 5%+ holder (13D) | 4,313,558 | 22.06% | 2025-04-03 |
| FMR, LLC | Institution (13F) | 2,830,378 | 14.48% | 2026-06-30 |
| TCG Crossover Management, LLC | Institution (13F) | 1,204,891 | 6.16% | 2026-06-30 |
| Chen Yu | 5%+ holder (13G) | 1,169,760 | 5.98% | 2026-02-12 |
| Aberdeen Group plc | Institution (13G, 5%+) | 1,141,824 | 5.84% | 2025-12-31 |
| VV Manager II, LLC | 5%+ holder (13D) | 1,028,674 | 5.26% | 2025-02-05 |
| Blackrock Inc. | Institution (13F) | 862,592 | 4.41% | 2026-06-30 |
| First Light Asset Management, LLC | Institution (13F) | 800,726 | 4.10% | 2026-06-30 |
| Terrance McGuire | 5%+ holder (13D) | 657,976 | 3.37% | 2025-04-03 |
| Baker Bros. Advisors, LP | Institution (13F) | 607,788 | 3.11% | 2026-06-30 |
| 5AM Venture Management, LLC | Institution (13F) | 606,660 | 3.10% | 2026-06-30 |
| Braidwell LP | Institution (13F) | 596,900 | 3.05% | 2026-06-30 |
Share count 19,549,366 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-03 filed 2026-09-08 |
McNamara Peter |
Option award (A) | 21,000 | – | – |
| 2026-09-03 filed 2026-09-08 |
Ruddy Marcella K. |
Option award (A) | 24,250 | – | – |
| 2026-09-03 filed 2026-09-08 |
REICIN ALISE |
Option award (A) | 69,250 | – | – |
| 2026-09-03 filed 2026-09-08 |
Schwabish Marc |
Option award (A) | 17,750 | – | – |
| 2026-09-03 filed 2026-09-08 |
Lochner Daniel |
Option award (A) | 24,250 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TECX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →